Telum Therapeutics raised €18 million to advance treatments for hospital-acquired infections

7 views0 likes0 comments

Originally published byEU-Startups

Telum Therapeutics, a Spanish biotechnology company, today announced the successful completion of an €18 million Series A financing to advance its lead program targeting hospital-acquired (HABP) and ventilator-associated bacterial pneumonia (VABP). AMR Action Fund led the financing round, with participation from new investor Inveready and continued support from existing investors Invivo Partners, CDTI with its […]

The post Telum Therapeutics raised €18 million to advance treatments for hospital-acquired infections appeared first on EU-Startups.